Effectiveness the pharmaceutical care in diabetic patients
Objective: To determine the effectiveness of pharmaceutical care to improve control of type-2 diabetes mellitus. Methods: We carried out pharmacotherapeutical intervention during 19 months on patients with type-2 diabetes mellitus who were affiliate members of the contributive regime of the General...
Gespeichert in:
| Veröffentlicht in: | Colombia médica (Cali, Colombia) Colombia), 2011-01, Vol.42 (1), p.72-80 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 80 |
|---|---|
| container_issue | 1 |
| container_start_page | 72 |
| container_title | Colombia médica (Cali, Colombia) |
| container_volume | 42 |
| creator | Machado-Alba, Jorge E Torres-Rodríguez, Sandra Vallejos-Narváez, Alvaro |
| description | Objective: To determine the effectiveness of pharmaceutical care to
improve control of type-2 diabetes mellitus. Methods: We carried out
pharmacotherapeutical intervention during 19 months on patients with
type-2 diabetes mellitus who were affiliate members of the contributive
regime of the General System for Healthcare and Social Security in
Bogotá and Cartagena. Through an interview and evaluation of
medical records, we obtained information about antidiabetic medications
used, doses, other medications, along with Hemoglobin A1c level,
arterial pressure, serum low-density lipoprotein cholesterol level,
nephropathy screening, retinal screening, foot exams in the last year
and problems associated with medication use by means of the DADER
method Negative Outcomes Associated with Medication (NOM). Results:
The study had a sample of 143 patients (64 intervened and 79 controls)
with female predominance (67.1% and 53.1%, respectively), mean age of
63.9±11.2 years. The patients in both groups were taking an
average of 6.0±2.7 medications. Initial HbA1c mean was 7.7% and
7.8%, without improvement by the end of the study (7.4% for those
intervened and 7.8% for the control group). Hypertension (81.1%) and
dyslipidemia (62.9%) were the most important comorbidities. About 50.4%
of NOM were of effectiveness, follows 31.3% of necessity. The mean cost
per patient in controls was 1.4 greater than for the intervened group.
Conclusions: Increased effectiveness of the antidiabetic therapy was
not demonstrated in patients intervened with pharmacotherapeutical
monitoring, but we did obtain a reduction in healthcare costs.
Objetivo: Determinar la efectividad del seguimiento
farmacoterapéutico para mejorar el control de los pacientes
diabéticos tipo 2. Métodos: Se realizó
intervención farmacoterapéutica durante 19 meses a pacientes
con diabetes mellitus tipo 2, afiliados al régimen contributivo
del Sistema General de Seguridad Social en Salud en Bogotá y
Cartagena. Mediante entrevista y revisión de la historia
clínica, se obtuvo información sobre medicamentos
antidiabéticos utilizados, dosis, comedicación, resultados en
último año de HbA1c, tensión arterial, perfil
lipídico, albuminuria, examen oftalmológico, valoración
de pies y los Resultados Negativos Asociados con la Medicación
(RNM) y se siguió la metodología DADER. Resultados:
Participaron 143 pacientes, 64 intervenidos y 79 controles, con
predominio de mujeres (67.1% y 53.1%, respectivamente), promedio de
edad 63.9±11.2 a |
| doi_str_mv | 10.25100/cm.v42i1.753 |
| format | Article |
| fullrecord | <record><control><sourceid>bioline_cross</sourceid><recordid>TN_cdi_crossref_primary_10_25100_cm_v42i1_753</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>cria_bioline_rc_rc11010</sourcerecordid><originalsourceid>FETCH-LOGICAL-b354t-9db53509a582dc204cd5d312fc139438e3a2ca569cebfd3d9bc6ad6c1d9a3de63</originalsourceid><addsrcrecordid>eNo9j1FLwzAUhYMoWKePvvcPtCa5Tdf4JmM6YeCLPofbm1sWabuR1IH_3rKpcODA4ePAJ8S9kqU2SsoHGspjpYMqlwYuRKZqsyysgepSZFJpWTSg9bW4SelTSm2rRmbicd11TFM48sgp5dOO88MO44DEX1Mg7HPCyHkYcx-w5XnKDzgFHqd0K6467BPf_fZCfDyv31ebYvv28rp62hYtmGoqrG8NGGnRNNqTlhV540HpjhTYChoG1ISmtsRt58Hblmr0NSlvETzXsBDF-ZfiPqXInTvEMGD8dkq6k7ijwZ3E3Sw-8-WZb8O-DyP_4xQDur8x0hylpJLwA6nqXkE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Effectiveness the pharmaceutical care in diabetic patients</title><source>Bioline International</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Machado-Alba, Jorge E ; Torres-Rodríguez, Sandra ; Vallejos-Narváez, Alvaro</creator><creatorcontrib>Machado-Alba, Jorge E ; Torres-Rodríguez, Sandra ; Vallejos-Narváez, Alvaro</creatorcontrib><description>Objective: To determine the effectiveness of pharmaceutical care to
improve control of type-2 diabetes mellitus. Methods: We carried out
pharmacotherapeutical intervention during 19 months on patients with
type-2 diabetes mellitus who were affiliate members of the contributive
regime of the General System for Healthcare and Social Security in
Bogotá and Cartagena. Through an interview and evaluation of
medical records, we obtained information about antidiabetic medications
used, doses, other medications, along with Hemoglobin A1c level,
arterial pressure, serum low-density lipoprotein cholesterol level,
nephropathy screening, retinal screening, foot exams in the last year
and problems associated with medication use by means of the DADER
method Negative Outcomes Associated with Medication (NOM). Results:
The study had a sample of 143 patients (64 intervened and 79 controls)
with female predominance (67.1% and 53.1%, respectively), mean age of
63.9±11.2 years. The patients in both groups were taking an
average of 6.0±2.7 medications. Initial HbA1c mean was 7.7% and
7.8%, without improvement by the end of the study (7.4% for those
intervened and 7.8% for the control group). Hypertension (81.1%) and
dyslipidemia (62.9%) were the most important comorbidities. About 50.4%
of NOM were of effectiveness, follows 31.3% of necessity. The mean cost
per patient in controls was 1.4 greater than for the intervened group.
Conclusions: Increased effectiveness of the antidiabetic therapy was
not demonstrated in patients intervened with pharmacotherapeutical
monitoring, but we did obtain a reduction in healthcare costs.
Objetivo: Determinar la efectividad del seguimiento
farmacoterapéutico para mejorar el control de los pacientes
diabéticos tipo 2. Métodos: Se realizó
intervención farmacoterapéutica durante 19 meses a pacientes
con diabetes mellitus tipo 2, afiliados al régimen contributivo
del Sistema General de Seguridad Social en Salud en Bogotá y
Cartagena. Mediante entrevista y revisión de la historia
clínica, se obtuvo información sobre medicamentos
antidiabéticos utilizados, dosis, comedicación, resultados en
último año de HbA1c, tensión arterial, perfil
lipídico, albuminuria, examen oftalmológico, valoración
de pies y los Resultados Negativos Asociados con la Medicación
(RNM) y se siguió la metodología DADER. Resultados:
Participaron 143 pacientes, 64 intervenidos y 79 controles, con
predominio de mujeres (67.1% y 53.1%, respectivamente), promedio de
edad 63.9±11.2 años. Los pacientes de ambos grupos tomaban en
promedio 6.0±2.7 medicamentos. La HbA1c inicial tuvo un promedio
de 7.7% y 7.8% y al finalizar el estudio los valores fueron de 7.4% y
7.8%, respectivamente en cada grupo. El 50.4% de los RNM fueron de
efectividad, seguido de 31.3% de necesidad. En la visita inicial y
final la recomendación farmacéutica fue aceptada y el
problema de salud resuelto en 72 casos (42.9% de RNM) y en 46 casos
(38.3% de RNM), respectivamente. El cociente medio del costo por
paciente en el grupo control fue 1.4 veces mayor que en el intervenido.
Discusión: No se demostró aumento en la efectividad de la
terapia antidiabética en pacientes intervenidos con seguimiento
farmacoterapéutico, pero se consiguió una reducción en
costos de la atención sanitaria.</description><identifier>ISSN: 0120-8322</identifier><identifier>EISSN: 1657-9534</identifier><identifier>DOI: 10.25100/cm.v42i1.753</identifier><language>eng</language><publisher>Universidad del Valle - Facultad de Salud</publisher><subject>Agentes hipoglucémicos ; Colombia ; Diabetes mellitus ; Glucosylated hemoglobin A ; Hemoglobina A glucosilada ; Hypoglycemic agents ; Pharmaceutical services ; Servicios farmacéuticos</subject><ispartof>Colombia médica (Cali, Colombia), 2011-01, Vol.42 (1), p.72-80</ispartof><rights>Copyright 2011 Colombia Médica.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b354t-9db53509a582dc204cd5d312fc139438e3a2ca569cebfd3d9bc6ad6c1d9a3de63</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908,79177</link.rule.ids></links><search><creatorcontrib>Machado-Alba, Jorge E</creatorcontrib><creatorcontrib>Torres-Rodríguez, Sandra</creatorcontrib><creatorcontrib>Vallejos-Narváez, Alvaro</creatorcontrib><title>Effectiveness the pharmaceutical care in diabetic patients</title><title>Colombia médica (Cali, Colombia)</title><description>Objective: To determine the effectiveness of pharmaceutical care to
improve control of type-2 diabetes mellitus. Methods: We carried out
pharmacotherapeutical intervention during 19 months on patients with
type-2 diabetes mellitus who were affiliate members of the contributive
regime of the General System for Healthcare and Social Security in
Bogotá and Cartagena. Through an interview and evaluation of
medical records, we obtained information about antidiabetic medications
used, doses, other medications, along with Hemoglobin A1c level,
arterial pressure, serum low-density lipoprotein cholesterol level,
nephropathy screening, retinal screening, foot exams in the last year
and problems associated with medication use by means of the DADER
method Negative Outcomes Associated with Medication (NOM). Results:
The study had a sample of 143 patients (64 intervened and 79 controls)
with female predominance (67.1% and 53.1%, respectively), mean age of
63.9±11.2 years. The patients in both groups were taking an
average of 6.0±2.7 medications. Initial HbA1c mean was 7.7% and
7.8%, without improvement by the end of the study (7.4% for those
intervened and 7.8% for the control group). Hypertension (81.1%) and
dyslipidemia (62.9%) were the most important comorbidities. About 50.4%
of NOM were of effectiveness, follows 31.3% of necessity. The mean cost
per patient in controls was 1.4 greater than for the intervened group.
Conclusions: Increased effectiveness of the antidiabetic therapy was
not demonstrated in patients intervened with pharmacotherapeutical
monitoring, but we did obtain a reduction in healthcare costs.
Objetivo: Determinar la efectividad del seguimiento
farmacoterapéutico para mejorar el control de los pacientes
diabéticos tipo 2. Métodos: Se realizó
intervención farmacoterapéutica durante 19 meses a pacientes
con diabetes mellitus tipo 2, afiliados al régimen contributivo
del Sistema General de Seguridad Social en Salud en Bogotá y
Cartagena. Mediante entrevista y revisión de la historia
clínica, se obtuvo información sobre medicamentos
antidiabéticos utilizados, dosis, comedicación, resultados en
último año de HbA1c, tensión arterial, perfil
lipídico, albuminuria, examen oftalmológico, valoración
de pies y los Resultados Negativos Asociados con la Medicación
(RNM) y se siguió la metodología DADER. Resultados:
Participaron 143 pacientes, 64 intervenidos y 79 controles, con
predominio de mujeres (67.1% y 53.1%, respectivamente), promedio de
edad 63.9±11.2 años. Los pacientes de ambos grupos tomaban en
promedio 6.0±2.7 medicamentos. La HbA1c inicial tuvo un promedio
de 7.7% y 7.8% y al finalizar el estudio los valores fueron de 7.4% y
7.8%, respectivamente en cada grupo. El 50.4% de los RNM fueron de
efectividad, seguido de 31.3% de necesidad. En la visita inicial y
final la recomendación farmacéutica fue aceptada y el
problema de salud resuelto en 72 casos (42.9% de RNM) y en 46 casos
(38.3% de RNM), respectivamente. El cociente medio del costo por
paciente en el grupo control fue 1.4 veces mayor que en el intervenido.
Discusión: No se demostró aumento en la efectividad de la
terapia antidiabética en pacientes intervenidos con seguimiento
farmacoterapéutico, pero se consiguió una reducción en
costos de la atención sanitaria.</description><subject>Agentes hipoglucémicos</subject><subject>Colombia</subject><subject>Diabetes mellitus</subject><subject>Glucosylated hemoglobin A</subject><subject>Hemoglobina A glucosilada</subject><subject>Hypoglycemic agents</subject><subject>Pharmaceutical services</subject><subject>Servicios farmacéuticos</subject><issn>0120-8322</issn><issn>1657-9534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>RBI</sourceid><recordid>eNo9j1FLwzAUhYMoWKePvvcPtCa5Tdf4JmM6YeCLPofbm1sWabuR1IH_3rKpcODA4ePAJ8S9kqU2SsoHGspjpYMqlwYuRKZqsyysgepSZFJpWTSg9bW4SelTSm2rRmbicd11TFM48sgp5dOO88MO44DEX1Mg7HPCyHkYcx-w5XnKDzgFHqd0K6467BPf_fZCfDyv31ebYvv28rp62hYtmGoqrG8NGGnRNNqTlhV540HpjhTYChoG1ISmtsRt58Hblmr0NSlvETzXsBDF-ZfiPqXInTvEMGD8dkq6k7ijwZ3E3Sw-8-WZb8O-DyP_4xQDur8x0hylpJLwA6nqXkE</recordid><startdate>20110101</startdate><enddate>20110101</enddate><creator>Machado-Alba, Jorge E</creator><creator>Torres-Rodríguez, Sandra</creator><creator>Vallejos-Narváez, Alvaro</creator><general>Universidad del Valle - Facultad de Salud</general><scope>RBI</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20110101</creationdate><title>Effectiveness the pharmaceutical care in diabetic patients</title><author>Machado-Alba, Jorge E ; Torres-Rodríguez, Sandra ; Vallejos-Narváez, Alvaro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b354t-9db53509a582dc204cd5d312fc139438e3a2ca569cebfd3d9bc6ad6c1d9a3de63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Agentes hipoglucémicos</topic><topic>Colombia</topic><topic>Diabetes mellitus</topic><topic>Glucosylated hemoglobin A</topic><topic>Hemoglobina A glucosilada</topic><topic>Hypoglycemic agents</topic><topic>Pharmaceutical services</topic><topic>Servicios farmacéuticos</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Machado-Alba, Jorge E</creatorcontrib><creatorcontrib>Torres-Rodríguez, Sandra</creatorcontrib><creatorcontrib>Vallejos-Narváez, Alvaro</creatorcontrib><collection>Bioline International</collection><collection>CrossRef</collection><jtitle>Colombia médica (Cali, Colombia)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Machado-Alba, Jorge E</au><au>Torres-Rodríguez, Sandra</au><au>Vallejos-Narváez, Alvaro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness the pharmaceutical care in diabetic patients</atitle><jtitle>Colombia médica (Cali, Colombia)</jtitle><date>2011-01-01</date><risdate>2011</risdate><volume>42</volume><issue>1</issue><spage>72</spage><epage>80</epage><pages>72-80</pages><issn>0120-8322</issn><eissn>1657-9534</eissn><abstract>Objective: To determine the effectiveness of pharmaceutical care to
improve control of type-2 diabetes mellitus. Methods: We carried out
pharmacotherapeutical intervention during 19 months on patients with
type-2 diabetes mellitus who were affiliate members of the contributive
regime of the General System for Healthcare and Social Security in
Bogotá and Cartagena. Through an interview and evaluation of
medical records, we obtained information about antidiabetic medications
used, doses, other medications, along with Hemoglobin A1c level,
arterial pressure, serum low-density lipoprotein cholesterol level,
nephropathy screening, retinal screening, foot exams in the last year
and problems associated with medication use by means of the DADER
method Negative Outcomes Associated with Medication (NOM). Results:
The study had a sample of 143 patients (64 intervened and 79 controls)
with female predominance (67.1% and 53.1%, respectively), mean age of
63.9±11.2 years. The patients in both groups were taking an
average of 6.0±2.7 medications. Initial HbA1c mean was 7.7% and
7.8%, without improvement by the end of the study (7.4% for those
intervened and 7.8% for the control group). Hypertension (81.1%) and
dyslipidemia (62.9%) were the most important comorbidities. About 50.4%
of NOM were of effectiveness, follows 31.3% of necessity. The mean cost
per patient in controls was 1.4 greater than for the intervened group.
Conclusions: Increased effectiveness of the antidiabetic therapy was
not demonstrated in patients intervened with pharmacotherapeutical
monitoring, but we did obtain a reduction in healthcare costs.
Objetivo: Determinar la efectividad del seguimiento
farmacoterapéutico para mejorar el control de los pacientes
diabéticos tipo 2. Métodos: Se realizó
intervención farmacoterapéutica durante 19 meses a pacientes
con diabetes mellitus tipo 2, afiliados al régimen contributivo
del Sistema General de Seguridad Social en Salud en Bogotá y
Cartagena. Mediante entrevista y revisión de la historia
clínica, se obtuvo información sobre medicamentos
antidiabéticos utilizados, dosis, comedicación, resultados en
último año de HbA1c, tensión arterial, perfil
lipídico, albuminuria, examen oftalmológico, valoración
de pies y los Resultados Negativos Asociados con la Medicación
(RNM) y se siguió la metodología DADER. Resultados:
Participaron 143 pacientes, 64 intervenidos y 79 controles, con
predominio de mujeres (67.1% y 53.1%, respectivamente), promedio de
edad 63.9±11.2 años. Los pacientes de ambos grupos tomaban en
promedio 6.0±2.7 medicamentos. La HbA1c inicial tuvo un promedio
de 7.7% y 7.8% y al finalizar el estudio los valores fueron de 7.4% y
7.8%, respectivamente en cada grupo. El 50.4% de los RNM fueron de
efectividad, seguido de 31.3% de necesidad. En la visita inicial y
final la recomendación farmacéutica fue aceptada y el
problema de salud resuelto en 72 casos (42.9% de RNM) y en 46 casos
(38.3% de RNM), respectivamente. El cociente medio del costo por
paciente en el grupo control fue 1.4 veces mayor que en el intervenido.
Discusión: No se demostró aumento en la efectividad de la
terapia antidiabética en pacientes intervenidos con seguimiento
farmacoterapéutico, pero se consiguió una reducción en
costos de la atención sanitaria.</abstract><pub>Universidad del Valle - Facultad de Salud</pub><doi>10.25100/cm.v42i1.753</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0120-8322 |
| ispartof | Colombia médica (Cali, Colombia), 2011-01, Vol.42 (1), p.72-80 |
| issn | 0120-8322 1657-9534 |
| language | eng |
| recordid | cdi_crossref_primary_10_25100_cm_v42i1_753 |
| source | Bioline International; EZB-FREE-00999 freely available EZB journals |
| subjects | Agentes hipoglucémicos Colombia Diabetes mellitus Glucosylated hemoglobin A Hemoglobina A glucosilada Hypoglycemic agents Pharmaceutical services Servicios farmacéuticos |
| title | Effectiveness the pharmaceutical care in diabetic patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T21%3A29%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-bioline_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20the%20pharmaceutical%20care%20in%20diabetic%20patients&rft.jtitle=Colombia%20m%C3%A9dica%20(Cali,%20Colombia)&rft.au=Machado-Alba,%20Jorge%20E&rft.date=2011-01-01&rft.volume=42&rft.issue=1&rft.spage=72&rft.epage=80&rft.pages=72-80&rft.issn=0120-8322&rft.eissn=1657-9534&rft_id=info:doi/10.25100/cm.v42i1.753&rft_dat=%3Cbioline_cross%3Ecria_bioline_rc_rc11010%3C/bioline_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |